Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.66 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.66 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.66 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.66 |
| ▸ | ACVR1 known ✓ | Q04771 | 1/20 | 0.66 |
| ▸ | AURKA | O14965 | 19/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 17/20 | 1.00 |
| ▸ | INCENP | Q9NQS7 | 17/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 0.66 |
| ▸ | STK10 | O94804 | 1/20 | 0.66 |
| ▸ | FER | P16591 | 1/20 | 0.66 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.66 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.66 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.66 |
| ▸ | TEC | P42680 | 1/20 | 0.66 |
| ▸ | ABL2 | P42684 | 1/20 | 0.66 |
| ▸ | FRK | P42685 | 1/20 | 0.66 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.66 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.66 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1501000 | 1.00 | AURKA (1.00) | AURKAAURKBINCENPPLK4JAK2 | |
| SCHEMBL10295420 | 0.99 | AURKA (0.98) | AURKAAURKBINCENPPLK4JAK2 | |
| Hydrochloric Acid SCHEMBL1501055 | 0.88 | AURKA (1.00) | AURKAAURKBINCENPPLK4JAK2 | |
| Hydrochloric Acid SCHEMBL1501052 | 0.88 | AURKA (1.00) | AURKAAURKBINCENPPLK4JAK2 | |
| SCHEMBL10295433 | 0.87 | AURKA (0.98) | AURKAAURKBINCENPPLK4JAK2 | |
| Hydrochloric Acid SCHEMBL1501408 | 0.84 | AURKA (1.00) | AURKAAURKBINCENPPLK4JAK2 | |
| Hydrochloric Acid SCHEMBL1501405 | 0.84 | AURKA (1.00) | AURKAAURKBINCENPPLK4JAK2 | |
| SCHEMBL1501340 | 0.83 | AURKA (0.98) | AURKAAURKBINCENPPLK4JAK2 | |
| SCHEMBL1501343 | 0.83 | AURKA (0.98) | AURKAAURKBINCENPPLK4JAK2 | |
| Hydrochloric Acid SCHEMBL1501426 | 0.82 | AURKA (1.00) | AURKAAURKBINCENPPLK4JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2062887-B1 | AMINOPYRIDINE DERIVATIVE HAVING AURORA A-SELECTIVE INHIBITORY ACTIVITY | MSD KK (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-7915263-B2 | Aurora kinase inhibitors such as trans-4-(3-chloro-2-fluorophenoxy)-1-((6-(1,3-thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexanecarboxylic acid; antitumor agents; combination therapy with other drugs and biodrugs such as paclitaxel or docetaxel | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20100016335-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | IWASAWA YOSHIKAZU | 2010-01-21 | — | — | US | disclosed |
| EP-2062887-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20080058347-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016335-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | JAK2 301/4885ABL1 21/4885RET 2075/4885 |
| US-20080058347-A1 | Novel aminopyridine derivatives having aurora a selective inhibitory action | AURKA, AURKC, AURKB | JAK2 301/4885ABL1 21/4885RET 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.